SCHEMBL5161068

SCHEMBL5161068

CCCCCCCCCCn1cnc2c(Cl)nc(Cl)nc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.51
HDAC2 Q92769 2/20 0.51
CTSL P07711 2/20 0.45
P2RX7 Q99572 1/20 0.45
ADORA2A P29274 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
PDGFRA P16234 3/20 0.43
CCNE1 P24864 3/20 0.43
CDK2 P24941 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161283 0.98 HDAC1 (0.49) HDAC1HDAC2CTSLP2RX7ADORA2A
SCHEMBL5158596 0.88 P2RX7 (0.49) HDAC1HDAC2P2RX7ADORA2AHDAC3
SCHEMBL30332411 0.88 P2RX7 (0.49) HDAC1HDAC2P2RX7ADORA2AHDAC3
SCHEMBL3441038 0.86 CDK1 (0.57) HDAC1HDAC2CTSLADORA2APDGFRA
SCHEMBL8464465 0.85 TK1 (0.51) HDAC1HDAC2CTSLP2RX7ADORA2A
SCHEMBL3441032 0.84 CDK1 (0.59) HDAC1HDAC2ADORA2ACCNE1CDK2
SCHEMBL4847394 0.84 HSP90AB1 (0.53) ADORA2ACCNE1CDK2CYP1A2
SCHEMBL21268667 0.81 CTSL (0.41) HDAC1HDAC2CTSLADORA2APDGFRA
SCHEMBL29388425 0.81 CTSL (0.41) HDAC1HDAC2CTSLADORA2APDGFRA
SCHEMBL29444616 0.81 CDK1 (0.51) HDAC1HDAC2P2RX7ADORA2AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
EP-1456209-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2004-09-15 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed
WO-2003051882-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 HDAC1 2520/4885HDAC2 1046/4885CTSL 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.